Cited 14 times in
Fludarabine, cytarabine, and attenuated-dose idarubicin (m-FLAI) combination therapy for elderly acute myeloid leukemia patients
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 민유홍 | - |
dc.contributor.author | 정준원 | - |
dc.date.accessioned | 2014-12-18T08:38:39Z | - |
dc.date.available | 2014-12-18T08:38:39Z | - |
dc.date.issued | 2013 | - |
dc.identifier.issn | 0361-8609 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/86689 | - |
dc.description.abstract | We performed a phase II trial to evaluate the efficacy and safety of the modified fludarabine, cytarabine, and attenuated-dose idarubicin (m-FLAI) regimen in elderly acute myeloid leukemia (AML) patients. Elderly (≥60 years) AML patients who had not previously received chemotherapy were enrolled in the study. Patients received two consecutive cycles of m-FLAI chemotherapy as an induction. The m-FLAI regimen comprised fludarabine (25 mg/m(2) , days 1-4), cytarabine (1,000 mg/m(2) , days 1-4), and attenuated-dose idarubicin (5 mg/m(2) , days 1-3). The primary end point was complete remission (CR) rate. Secondary end points were overall survival (OS), event-free survival (EFS), and treatment-related mortality (TRM). There were 108 patients (median age 68.4 years, M:F = 64:44) enrolled in the study. CR was achieved in 56.5% of patients, and the TRM rate was 21.3%. Median OS and median EFS were 10.2 and 6.6 months, respectively. The mortality at 30 and 60 days was 15 and 21%, respectively. Performance status and comorbidity did not have prognostic value in this patient cohort. Bone marrow expression of CD117 was associated with increased EFS and OS. m-FLAI is an effective induction regimen for previously untreated AML in elderly patients. In addition, bone-marrow CD117 expression is an independent favorable prognostic factor in elderly AML patients. (ClinicalTrials.gov number, NCT01247493). | - |
dc.description.statementOfResponsibility | open | - |
dc.relation.isPartOf | AMERICAN JOURNAL OF HEMATOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Aged, 80 and over | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/administration & dosage* | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/adverse effects | - |
dc.subject.MESH | Bone Marrow/metabolism* | - |
dc.subject.MESH | Cohort Studies | - |
dc.subject.MESH | Cytarabine/administration & dosage | - |
dc.subject.MESH | Cytarabine/adverse effects | - |
dc.subject.MESH | Disease-Free Survival | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Gene Expression Regulation, Leukemic* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Idarubicin/administration & dosage | - |
dc.subject.MESH | Idarubicin/adverse effects | - |
dc.subject.MESH | Leukemia, Myeloid, Acute*/drug therapy | - |
dc.subject.MESH | Leukemia, Myeloid, Acute*/metabolism | - |
dc.subject.MESH | Leukemia, Myeloid, Acute*/mortality | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Proto-Oncogene Proteins c-kit/biosynthesis* | - |
dc.subject.MESH | Survival Rate | - |
dc.subject.MESH | Time Factors | - |
dc.subject.MESH | Vidarabine/administration & dosage | - |
dc.subject.MESH | Vidarabine/adverse effects | - |
dc.subject.MESH | Vidarabine/analogs & derivatives | - |
dc.title | Fludarabine, cytarabine, and attenuated-dose idarubicin (m-FLAI) combination therapy for elderly acute myeloid leukemia patients | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Inho Kim | - |
dc.contributor.googleauthor | Youngil Koh | - |
dc.contributor.googleauthor | Sung-Soo Yoon | - |
dc.contributor.googleauthor | Seonyang Park | - |
dc.contributor.googleauthor | Byoung Kook Kim | - |
dc.contributor.googleauthor | Dae-Young Kim | - |
dc.contributor.googleauthor | Jung-Hee Lee | - |
dc.contributor.googleauthor | Kyoo-Hyung Lee | - |
dc.contributor.googleauthor | June-Won Cheong | - |
dc.contributor.googleauthor | Hong-Kee Lee | - |
dc.contributor.googleauthor | Sung-Hyun Kim | - |
dc.contributor.googleauthor | Hyuk Kim | - |
dc.contributor.googleauthor | Young Don Joo | - |
dc.contributor.googleauthor | Sang-Min Lee | - |
dc.contributor.googleauthor | Jong-Ho Won | - |
dc.contributor.googleauthor | Sung-Kyu Park | - |
dc.contributor.googleauthor | Dae-Sik Hong | - |
dc.contributor.googleauthor | Se-Hyung Kim | - |
dc.contributor.googleauthor | Sang Kyun Sohn | - |
dc.contributor.googleauthor | Chul-Soo Kim | - |
dc.contributor.googleauthor | Eunkyung Park | - |
dc.contributor.googleauthor | Min Kyoung Kim | - |
dc.contributor.googleauthor | Moo Rim Park | - |
dc.contributor.googleauthor | Je-Hwan Lee | - |
dc.contributor.googleauthor | Yoo Hong Min | - |
dc.identifier.doi | 10.1002/ajh.23337 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A01407 | - |
dc.contributor.localId | A03729 | - |
dc.relation.journalcode | J00085 | - |
dc.identifier.eissn | 1096-8652 | - |
dc.identifier.pmid | 23077109 | - |
dc.identifier.url | http://onlinelibrary.wiley.com/doi/10.1002/ajh.23337/abstract;jsessionid=D00C7A38C0DAF6C87242A7BB4C5F513D.f04t03 | - |
dc.subject.keyword | Aged | - |
dc.subject.keyword | Aged, 80 and over | - |
dc.subject.keyword | Antineoplastic Combined Chemotherapy Protocols/administration & dosage* | - |
dc.subject.keyword | Antineoplastic Combined Chemotherapy Protocols/adverse effects | - |
dc.subject.keyword | Bone Marrow/metabolism* | - |
dc.subject.keyword | Cohort Studies | - |
dc.subject.keyword | Cytarabine/administration & dosage | - |
dc.subject.keyword | Cytarabine/adverse effects | - |
dc.subject.keyword | Disease-Free Survival | - |
dc.subject.keyword | Female | - |
dc.subject.keyword | Gene Expression Regulation, Leukemic* | - |
dc.subject.keyword | Humans | - |
dc.subject.keyword | Idarubicin/administration & dosage | - |
dc.subject.keyword | Idarubicin/adverse effects | - |
dc.subject.keyword | Leukemia, Myeloid, Acute*/drug therapy | - |
dc.subject.keyword | Leukemia, Myeloid, Acute*/metabolism | - |
dc.subject.keyword | Leukemia, Myeloid, Acute*/mortality | - |
dc.subject.keyword | Male | - |
dc.subject.keyword | Middle Aged | - |
dc.subject.keyword | Proto-Oncogene Proteins c-kit/biosynthesis* | - |
dc.subject.keyword | Survival Rate | - |
dc.subject.keyword | Time Factors | - |
dc.subject.keyword | Vidarabine/administration & dosage | - |
dc.subject.keyword | Vidarabine/adverse effects | - |
dc.subject.keyword | Vidarabine/analogs & derivatives | - |
dc.contributor.alternativeName | Min, Yoo Hong | - |
dc.contributor.alternativeName | Cheong, June Won | - |
dc.contributor.affiliatedAuthor | Min, Yoo Hong | - |
dc.contributor.affiliatedAuthor | Cheong, June-Won | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 88 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 10 | - |
dc.citation.endPage | 15 | - |
dc.identifier.bibliographicCitation | AMERICAN JOURNAL OF HEMATOLOGY, Vol.88(1) : 10-15, 2013 | - |
dc.identifier.rimsid | 29144 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.